Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) is set to release its Q3 2024 earnings on Nov 12, 2024. The consensus estimate for ...

On Monday, Lexicon Pharmaceuticals Inc (LXRX) stock saw a modest uptick, ending the day at $1.27 which represents no change from the prior close of of $1.27. The stock opened at $1.26 and touched a ...

Analysts are estimating that Lexicon Pharmaceuticals will report an earnings per share (EPS) of $-0.16. The announcement from Lexicon Pharmaceuticals is eagerly anticipated, with investors seeking ...

Lexicon Pharmaceuticals, Inc. - GlobeNewswire - Wed Nov 6, 7:00AM CST THE WOODLANDS, Texas, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its ...

On Friday, Lexicon Pharmaceuticals Inc (LXRX) stock saw a decline, ending the day at $1.27 which represents a decrease of $-0.03 or -2.31% from the prior close of $1.3. The stock opened at $1.3 and ...

Lexicon Pharmaceuticals (NASDAQ:LXRX) is scheduled to announce Q3 earnings results on Tuesday, November 12th, after market ...

THE WOODLANDS, Texas, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Jefferies London Global Healthcare Conference.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

THE WOODLANDS, Texas, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Jefferies London Global Healthcare Conference. Lexicon ...

Lexicon (LXRX) announced the peer-reviewed Journal of American Society of Nephrology, or JASN, has published a research paper analyzing the ...